Exclusive distribution agreement means Medical Kiwi ready to sell imported CBD products in early 2020

An exclusive distribution agreement with United Kingdom CBD product distributor Vitality CBD is an exciting step towards Medical Kiwi’s plans to provide New Zealanders with access to safe, high-quality, affordable medicinal and nutraceutical cannabis products.

The agreement, signed this week, enables Medical Kiwi to import and sell CBD products as soon as the Medicinal Cannabis Scheme is operational in the first quarter of 2020. “We will sell Vitality CBD’s full range of medicinal cannabis products,” says Chairman, Aldo Miccio. The 0% THC cannabis collection includes sprays, drops, skin cream, balms and e-liquids and is currently sold across the UK in Boots stores, Tesco supermarkets, pharmacies and health stores.

“This agreement is part of our strategy to import and distribute our overseas partner’s branded medicinal and nutraceutical products on an ongoing basis, to create accessibility while our own locally cultivated Medical Kiwi products are being developed,” says Aldo.

“We will start construction on our state-of-the-art facility late next year and it will take a number of years to reach full capacity, so we plan to advance our vision of making medicinal cannabis products available to New Zealanders by selling imported product as soon as the law allows.”

Plans for the distribution agreement have been in the pipeline since Aldo met with Vitality CBD earlier in the year when he was in the UK to launch the Series A investor offer.

Many of the details about where and how the products will be sold and how much they will cost will be determined once the Medicinal Cannabis Scheme is in place. “Our business model is for Medical Kiwi’s New Zealand-made and imported products to cost significantly less than current prescription prices. Once the Medicinal Cannabis Scheme is in place, we will be able to share a lot more about what that means,” says Aldo.